Full Press Release Details
Pharmaceuticals Successfully Completes
1B Clinical Trials Of Oral Insulin Capsule
2A Trials Planned For Second Quarter 2008
Israel - March 11, 2008 -- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB
http://www.oramed.com), a developer of oral delivery systems, has successfully
completed Phase 1B clinical trials of its oral insulin capsule. The Phase 1B
trial, which utilized healthy volunteers, was focused on finding the optimal
dosage for the formulation of Oramed's oral insulin product.
plans to commence Phase 2A clinical trials in Israel in the second quarter
2008. The Phase 2A study is designed to evaluate the safety and efficacy of
Oramed's oral insulin in Type II Diabetic volunteers. Oramed is simultaneously
working on completing the requirements for an IND for Phase 2 FDA approved
Oramed Pharmaceuticals
Pharmaceuticals is an Israeli-based company focused on the development
delivery solutions based on proprietary technology. Diabetes is one of the
rapidly growing diseases in the world and is one that requires constant and
unpleasant monitoring and drug therapy regimens. Oramed is currently
an orally ingestible insulin capsule for the treatment of diabetes. The
is also pursuing the development of oral delivery solutions for other drugs
more information please visit our website at: www.oramed.com.
the statements contained in this press release are forward-looking statements
which involve known and unknown risks, uncertainties, and other factors which
may cause the actual results, performance or achievements of the company, or
industry results, to be materially different from any future results,
performance or achievements expressed or implied by such forward looking
statements, including the risks and uncertainties related to the progress,
timing, cost, and results of clinical trials and product development programs;
difficulties or delays in obtaining regulatory approval for our product
candidates; competition from other pharmaceutical or biotechnology companies;
and the company's ability to obtain additional funding required to conduct its
research, development and commercialization activities. Please refer to the
company's filings with the Securities and Exchange commission for a
comprehensive list of risk factors that could cause actual results, performance
or achievements of the company to differ materially from those expressed or
implied in such forward looking statements. The company undertakes no obligation
to update or revise any forward-looking statements
Pharmaceuticals, Inc
Granito, Steve Melfi